Dominic E. Shaw

TL;DR: Cluster analysis offers a novel multidimensional approach for identifying asthma phenotypes that exhibit differences in clinical response to treatment algorithms, and is specific to refractory asthma.

TL;DR: Clustering based on clinicophysiologic parameters yielded 4 stable and reproducible clusters of asthmatic patients that associate with different pathobiological pathways.

TL;DR: T2-high severe asthma can be predicted to some extent from raised levels of FeNO, blood and sputum eosinophil counts, but serum IgE or serum periostin were poor predictors and better bedside biomarkers are needed to detect T2- high.

TL;DR: The IL-17-high asthma phenotype, characterized by bronchial epithelial dysfunction and upregulated antimicrobial and inflammatory response, resembles the immunophenotype of psoriasis, including activation of the thromboxane B2 pathway, which should be considered a biomarker for this phenotype in further studies, including clinical trials targeting IL- 17.

TL;DR: The proportion of patients with severe asthma in whom T2 biomarkers remained low when corticosteroid therapy was decreased to a minimum ICS dose was established.